PLX Stock Overview
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Protalix BioTherapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.20 |
| 52 Week High | US$3.55 |
| 52 Week Low | US$1.09 |
| Beta | 0.89 |
| 1 Month Change | -5.51% |
| 3 Month Change | -18.37% |
| 1 Year Change | -51.81% |
| 3 Year Change | -79.42% |
| 5 Year Change | -72.52% |
| Change since IPO | -99.56% |
Recent News & Updates
Shareholder Returns
| PLX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 5.3% | -2.5% | -3.2% |
| 1Y | -51.8% | -3.7% | 19.3% |
Return vs Industry: PLX underperformed the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: PLX underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| PLX volatility | |
|---|---|
| PLX Average Weekly Movement | 7.7% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PLX's share price has been volatile over the past 3 months.
Volatility Over Time: PLX's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 208 | Dror Bashan | www.protalix.com |
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases.
Protalix BioTherapeutics, Inc. Fundamentals Summary
| PLX fundamental statistics | |
|---|---|
| Market cap | US$86.20m |
| Earnings (TTM) | US$8.31m |
| Revenue (TTM) | US$65.49m |
10.5x
P/E Ratio1.3x
P/S RatioIs PLX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PLX income statement (TTM) | |
|---|---|
| Revenue | US$65.49m |
| Cost of Revenue | US$22.98m |
| Gross Profit | US$42.51m |
| Other Expenses | US$34.20m |
| Earnings | US$8.31m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.11 |
| Gross Margin | 64.91% |
| Net Profit Margin | 12.69% |
| Debt/Equity Ratio | 60.3% |
How did PLX perform over the long term?
See historical performance and comparison